LEARN MORE...

Johnson & Johnson Medical Enterprise Strategy and Performance Paper

Content type

User Generated

Subject

Management

Type

Research Paper

Uploaded By

jnzhalhzhevhxv

Pages

Showing Page:

1/16

Running head: MULTINATIONAL ENTERPRISE STRATEGY AND PERFORMANCE 1

Multinational Enterprise Strategy and Performance

Case Study of Johnson and Johnson Medical Ltd

by Student's Name

Code + Course Name

Professor's Name

University Name

City, State

Date

Showing Page:

2/16

MULTINATIONAL ENTERPRISE STRATEGY AND PERFORMANCE 2

Multinational Enterprise Strategy and Performance

Johnson & Johnson Medical Ltd is a private company that has existed for over thirty

years registered under the U.K. Company Act. It specializes in the manufacturing of medical

and dental instruments and supplies. It operates in 60 countries where it sells its products in

more than 200 countries.

Porter's Model Strategy

J & J builds its business strategy based on Porter's single diamond. The main

competitive advantage this company has is many assets. This company has been doing well

in its life since its revenue continues to beat that of its competitors. Its main competitor Pfizer

has revenue of $26 billion less compared to J & J, which generates 79.3 billion in a year.

Since the pharmaceutical industry requires substantial capital to run due to a lot of expenses

associated with the manufacturing of medicines, inventing new medicines and medical

services J & J becomes advantageous because it has set a lot of capital to fulfill these interests

(Vlados and Charis, 2019)

The demand for J & Js products is another advantage that makes it a leader in the

pharmaceutical market. The company has incomparable demand for its cancer drug called

Imbruvica, a blood thinner drug called Xarelto, and an autoimmune drug called Remicade.

However, other competing companies that produce the same drugs as J & J are emerging,

putting the company at risk. If these competitors remain in a small number, J & J will

continue being unbeatable. Also, J & J has developed relationships with segments such as

insurance companies, suppliers, doctors, and clinics, among others, a strategy that its

competitors have not been able to establish.

Competition between J & J and other companies in the same industry is very intense.

This pressure applies specifically to the manufacturing sector. The company faces a

Showing Page:

3/16

End of Preview - Want to read all 16 pages?

Access Now

Unformatted Attachment Preview

Running head: MULTINATIONAL ENTERPRISE STRATEGY AND PERFORMANCE 1 Multinational Enterprise Strategy and Performance Case Study of Johnson and Johnson Medical Ltd by Student's Name Code + Course Name Professor's Name University Name City, State Date MULTINATIONAL ENTERPRISE STRATEGY AND PERFORMANCE 2 Multinational Enterprise Strategy and Performance Johnson & Johnson Medical Ltd is a private company that has existed for over thirty years registered under the U.K. Company Act. It specializes in the manufacturing of medical and dental instruments and supplies. It operates in 60 countries where it sells its products in more than 200 countries. Porter's Model Strategy J & J builds its business strategy based on Porter's single diamond. The main competitive advantage this company has is many assets. This company has been doing well in its life since its revenue continues to beat that of its competitors. Its main competitor Pfizer has revenue of $26 billion less compared to J & J, which generates 79.3 billion in a year. Since the pharmaceutical industry requires substantial capital to run due to a lot of expenses associated with the manufacturing of medicines, inventing new medicines and medical services J & J becomes advantageous because it has set a lot of capital to fulfill these interests (Vlados and Charis, 2019) The demand for J & Js products is another advantage that makes it a leader in the pharmaceutical market. The company has incomparable demand for its cancer drug ...
Purchase document to see full attachment

Tags: Johnson & Johnson Johnson Johnson Medical Enterprise Strategy Enterprise Performance Porters Model Strategy